Banned Peptides in Sport: WADA Rules for BPC-157, CJC-1295 and Secretagogues

Banned peptides in sport are not a niche issue anymore. Recovery peptides, growth hormone secretagogues and "research" vials are discussed in gyms, forums, clinics and social feeds, often with the same loose language: faster healing, lean mass, better sleep, higher growth hormone, better recovery.

For an athlete subject to anti-doping rules, that language is a warning sign. The relevant question is not whether a peptide is easy to buy, whether a vendor shows a COA or whether another user says it helped an injury. The question is whether the current World Anti-Doping Agency Prohibited List, the athlete's sport rules and the peptide's mechanism make it prohibited.

This guide covers the peptides readers ask about most often: BPC-157, CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin, TB-500, thymosin beta-4 and IGF-1 analogs. It is not a replacement for official anti-doping advice, a Therapeutic Use Exemption review or legal counsel.

The Short Version

If a peptide is marketed for growth hormone, IGF-1, tissue growth, recovery or repair, an athlete should assume it needs official anti-doping review before use.

Why "Peptide" Is Not A Safe Category

"Peptide" only describes a molecular format: a chain of amino acids. It does not tell you whether a compound is permitted, prohibited, approved, investigational or research-only.

PeptideStat covers approved peptide drugs such as enfuvirtide, ziconotide, bivalirudin, desmopressin and teriparatide. Those are not the same as a vendor-labeled recovery peptide. They have specific labels, routes, warnings and indications.

Sport rules add a separate layer. A medically approved product can still require checking, and an unapproved research product can be prohibited even when it is not named in a forum list. For athletes, the official list and the athlete's anti-doping organization matter more than product marketing.

The WADA Buckets That Catch Peptides

WADA's Prohibited List is the international standard many sport organizations use. It is updated at least annually, and athletes need the current version, not an old screenshot or a vendor blog.

Peptides most often run into four practical anti-doping buckets:

1. Unapproved pharmacological substances. This is the S0 problem. If a compound has no current governmental approval for human therapeutic use and is not otherwise addressed, it can still be prohibited.
2. Growth hormone and growth hormone releasing factors. This is the CJC-1295, sermorelin and tesamorelin style problem.
3. Growth hormone secretagogues and ghrelin mimetics. This is the ipamorelin, GHRP-2, GHRP-6 and hexarelin style problem.
4. Growth factors, fragments and mimetics. This is where IGF-axis compounds, mechano growth factor language and repair-signaling claims become relevant.

That structure is why "not a steroid" is not a useful defense. Many banned peptides are not anabolic steroids. They are prohibited because they may affect growth hormone, growth factors, oxygen delivery, recovery biology or other performance-relevant systems.

BPC-157: Popular Recovery Claim, Prohibited Risk

BPC-157 is one of the most searched recovery peptides. It is marketed for tendon, ligament, gut and injury repair, and it has extensive animal literature. The problem is that animal repair models do not establish human efficacy, human dosing or long-term safety.

For sport, the key issue is even more direct: BPC-157 lacks current approval by a governmental regulatory health authority for human therapeutic use. That puts it squarely in the anti-doping risk zone for unapproved pharmacological substances. FDA's public compounding safety material also highlights limited safety information and peptide-quality concerns for BPC-157.

Detection science is not hypothetical either. A Drug Testing and Analysis paper reported detection and in vitro metabolism work for confiscated BPC-157 and MGF R23H. That paper should not be read as proof of human benefit. It is evidence that anti-doping laboratories have studied how to identify these compounds.

For the broader evidence picture, read BPC-157: Strong Animal Data, Almost No Human Evidence and BPC-157 vs TB-500.

CJC-1295, Ipamorelin And The GH Secretagogue Problem

CJC-1295 is a long-acting growth hormone releasing hormone analog. Human studies showed prolonged growth hormone and IGF-1 stimulation in healthy adults. That is the exact reason it attracts body-composition and recovery claims, and also the reason athletes should view it as high risk under anti-doping rules.

Ipamorelin is different mechanistically. It is a ghrelin-receptor growth hormone secretagogue rather than a GHRH analog. That distinction matters for biology, but it does not make the anti-doping issue disappear. The search intent is usually the same: raise GH in a way that feels cleaner or more selective than older secretagogues.

GHRP-2, GHRP-6 and hexarelin sit in the same practical conversation. They are often marketed for GH pulses, hunger, recovery or body composition. PeptideStat covers them as evidence-limited compounds, not approved athlete tools.

Detection work also exists for this category. One PubMed-indexed paper identified CJC-1295 in an unknown pharmaceutical preparation. Another reviewed advances in detecting growth hormone releasing hormone synthetic analogs. Neither paper turns the products into validated therapies. They show that the anti-doping lab side has a real analytical target.

Related guides: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, GHRP-2, GHRP-6 and Hexarelin.

TB-500, MGF And Growth-Factor Language

TB-500 is usually discussed as a thymosin beta-4 fragment or thymosin beta-4 related product. MGF refers to mechano growth factor, an IGF-1 splice-variant concept. Both are marketed around tissue repair or muscle repair, which is exactly the type of growth-factor framing that should make athletes stop.

The science is not simple. Thymosin beta-4 has real actin biology, wound and repair research, and some clinical ophthalmic investigation. That does not prove that retail TB-500 protocols improve human recovery. MGF has a mechanistic muscle-repair story, but direct human performance evidence is not established.

For sport, a compound does not become acceptable because the evidence is weak. Weak evidence can make the medical case worse while the anti-doping risk remains high.

Related guides: TB-500, Thymosin Beta-4, MGF, PEG-MGF, IGF-1 LR3 and IGF-1 DES.

Does A COA Or Supplement Label Help?

A COA may help answer whether a batch looks like the stated compound under a specific analytical method. It does not decide anti-doping status.

For athletes, the weak points are obvious:

• A supplement label may omit a peptide or use a synonym.
• A research vial may be mislabeled or contaminated.
• A COA may test identity but not every impurity.
• A product may contain a prohibited substance even if the seller never mentions WADA.
• An athlete can face consequences from a positive sample even if the product was marketed casually.

The peptide COA guide explains why purity and identity documents have limits. Those limits matter even more in sport because strict-liability rules often place responsibility on the athlete.

What Athletes Should Do Instead

This is the conservative workflow:

1. Check the current WADA Prohibited List and your sport's rules.
2. Check national anti-doping resources before using any peptide, injectable, nasal spray, "research" product or recovery compound.
3. Use official Therapeutic Use Exemption procedures when a medically necessary treatment may be prohibited.
4. Keep prescribed medications in original pharmacy packaging and retain documentation.
5. Avoid research peptides, unlabeled vials, clinic blends and supplement-style products that make human-use claims without regulated labeling.

Non-athletes should still care about the same evidence split. Anti-doping rules are sport-specific, but the safety gaps behind many recovery peptides are not.

Bottom Line

Banned peptides in sport are not limited to obvious anabolic drugs. WADA rules can catch unapproved substances, growth hormone releasing factors, growth hormone secretagogues, growth factors, fragments and mimetics.

BPC-157, CJC-1295, ipamorelin, GHRPs, TB-500, MGF and IGF-1 analogs all sit in high-risk territory for athletes. Some have interesting biology. Some have human pharmacology. Some have detection papers. None should be treated as a casual recovery supplement by anyone subject to anti-doping rules.

References

1. World Anti-Doping Agency. The Prohibited List. Page updated April 23, 2026.

2. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. PDF.

3. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current as of April 22, 2026.

4. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Testing and Analysis, 2017.

5. Henninge J, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis, 2010.

6. Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis, 2021.

7. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 2006.

8. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 2014.

9. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine, 2025.